Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

257.99 +7.66 (+3.06%)

Streaming Delayed Price Updated: 1:09 PM EDT, Aug 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

2 Dividend Stocks That Are No-Brainer Buys in August ↗

Today 1:20 EDT

They have businesses built to handle the toughest environments.

Via The Motley Fool

Topics Economy Intellectual Property

Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year ↗

August 16, 2026

AbbVie has another blockbuster business emerging.

Via The Motley Fool

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More ↗

August 14, 2026

The drugmaker should significantly mitigate its most important risk as it develops new products.

Via The Motley Fool

AbbVie (NYSE:ABBV) Shares Slip on Apogee Acquisition Despite In-Line Q2 Results ↗

July 31, 2026

Via Chartmill

Cannabis Theme's Hidden Strength: Established Players Outshining Pure Plays ↗

July 30, 2026

Via Chartmill

Topics Cannabis

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 14, 2026

Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.

Via The Motley Fool

Topics Intellectual Property

The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For

August 12, 2026

News Provided by USA News Group on behalf of Conexeu Sciences Inc.

From USA News Group

Via GlobeNewswire

2 Reasons to Like ABBV and 1 to Stay Skeptical

August 12, 2026

AbbVie has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.7% to $249.64 per...

Via StockStory

Topics Stocks Supply Chain

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 11, 2026

AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.

Via The Motley Fool

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026? ↗

August 11, 2026

Both of these stocks pay more than double the S&P 500 average of 1.1%.

Via The Motley Fool

Topics Stocks

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry? ↗

August 11, 2026

The pharmaceutical company hopes that another big-time acquisition will pay off.

Via The Motley Fool

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings? ↗

August 10, 2026

The stock is up just 8% this year and could prove to be an undervalued buy.

Via The Motley Fool

Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026? ↗

August 08, 2026

XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns.

Via The Motley Fool

Topics ETFs Economy

MarketBeat Week in Review – 08/03 - 08/07 ↗

August 08, 2026

A weekly roundup of MarketBeat analysis covering earnings from AbbVie, AMD, Palantir, Meta, Reddit, SpaceX and others, plus upcoming CPI and PPI inflation data.

Via MarketBeat

Topics Economy Intellectual Property

AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 07, 2026

AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.

Via The Motley Fool

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire? ↗

August 07, 2026

This risk is weighing on the stock.

Via The Motley Fool

The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call

August 07, 2026

AbbVie’s second quarter results reflected robust product performance but were met with cautious investor sentiment. Management credited double-digit sales gr...

Via StockStory

Topics Earnings

3 Cash-Producing Stocks for Long-Term Investors

August 06, 2026

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen ...

Via StockStory

Topics Energy

This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now ↗

August 05, 2026

There is no end in sight for the drugmaker's dividend growth streak.

Via The Motley Fool

Topics Intellectual Property

Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One

August 04, 2026

Issued on behalf of Conexeu Sciences Inc. (Nasdaq: CNXU)

From American News Group

Via GlobeNewswire

AbbVie (ABBV) Q2 2026 Earnings Call Transcript ↗

August 03, 2026

Revenue beat guidance as immunology and neuroscience portfolios drive growth.

Via The Motley Fool

Topics Earnings Economy

The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure ↗

August 03, 2026

As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV).

Via MarketBeat

Topics Artificial Intelligence ETFs Stocks

AbbVie Quietly Solved Its Biggest Problem—Now What? ↗

August 02, 2026

AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.

Via MarketBeat

Topics Intellectual Property

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset

August 01, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 10.2% year on year to $16.99 ...

Via StockStory

Why AbbVie Stock Slumped Today ↗

July 31, 2026

The company, one of the rare healthcare sector Dividend Kings, wasn't looking too royal on the last trading day of the week.

Via The Motley Fool

Topics Earnings

Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today ↗

July 31, 2026

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.65% on an annualized basis producing an average annual return of 16.8%. Currently, AbbVie has a market capitalization of...

Via Benzinga

AbbVie Q2 Earnings Call Highlights ↗

July 31, 2026

AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue...

Via MarketBeat

Topics ETFs Earnings

AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat ↗

July 31, 2026

AbbVie Inc. (NYSE: ABBV) shares are retreating Friday after trimming full-year adjusted EPS guidance below analyst targets.

Via Benzinga

AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue

July 31, 2026

Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-G...

Via StockStory

Get insights into the top movers in the S&P500 index of Friday's pre-market session. ↗

July 31, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.